SuperworthNeurocrine Biosciences EPS NBIX
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- $6.82
- Latest quarter, Q2 FY26
- $1.39
- +31% on a year earlier
- Fiscal year 2025
- $4.66
- +42% on the year before
Neurocrine Biosciences' earnings per share was $6.82 over the twelve months to Jun 30, 2026, up 102% on a year earlier.
In its latest quarter, Q2 FY26, it was $1.39, up 31% on the same quarter a year before.
Over the five fiscal years to FY2025 it grew 2% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $4.66 | +42% |
| FY2024 | $3.29 | +35% |
| FY2023 | $2.43 | +59% |
| FY2022 | $1.53 | +68% |
| FY2021 | $0.91 | −78% |
| FY2020 | $4.16 | +1161% |
| FY2019 | $0.33 | +94% |
| FY2018 | $0.17 | n/a |
| FY2017 | −$1.64 | n/a |
| FY2016 | −$1.62 | n/a |
| FY2015 | −$1.03 | n/a |
| FY2014 | −$0.82 | n/a |
| FY2013 | −$0.69 | −1086% |
| FY2012 | $0.07 | −90% |
| FY2011 | $0.67 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $1.39 | +31% | $6.82 | |
| Q1 FY26 | $1.91 | +2288% | $6.49 | |
| Q4 FY25 | $1.48 | +48% | $4.66 | |
| Q3 FY25 | $2.04 | +65% | $4.18 | |
| Q2 FY25 | $1.06 | +68% | $3.38 | |
| Q1 FY25 | $0.08 | −81% | $2.95 | |
| Q4 FY24 | $1.00 | −31% | $3.29 | |
| Q3 FY24 | $1.24 | +51% | $3.74 | |
| Q2 FY24 | $0.63 | −34% | $3.32 | |
| Q1 FY24 | $0.42 | n/a | $3.64 | |
| Q4 FY23 | $1.45 | +65% | $2.43 | |
| Q3 FY23 | $0.82 | +19% | $1.86 |
Against its peers
Companies in Biotechnology nearest Neurocrine Biosciences' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| NBIXNeurocrine Biosciences | $6.82 | +102% a year |
| HALOHalozyme Therapeutics | $3.35 | −23% a year |
| EXELExelixis | $3.18 | +53% a year |
| TECHBIO-TECHNE | $1.15 | +150% a year |
| RGENRepligen | $0.73 | |
| KRYSKrystal Biotech | $7.98 | +62% a year |
| INCYIncyte | $7.85 | +78% a year |
| UTHRUnited Therapeutics | $27.95 | +9% a year |
| ALNYAlnylam Pharmaceuticals | $5.93 | |
| ONCBeOne Medicines | $0.43 | |
| REGNRegeneron Pharmaceuticals | $40.44 | +2% a year |
| Peer median | $4.64 |
Where Neurocrine Biosciences ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Neurocrine Biosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.